Foghorn Therapeutics vs Arcus Biosciences
FHTX and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FHTX and RCUS compare
Arcus Biosciences is the larger company, worth 19 times as much as Foghorn Therapeutics ($2.3B against $122M).
Foghorn Therapeutics grew revenue faster over the last twelve months (357% versus −58.3% for Arcus Biosciences).
Foghorn Therapeutics keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with −453% at Arcus Biosciences.
Foghorn Therapeutics scores higher on the StockData Score (11 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FHTX | RCUS |
|---|---|---|
| Size and price | ||
| Market cap | $122M | $2.3B |
| Share price | $2.05 | $17.77 |
| Change, 1 year | −53.8% | −12.4% |
| Change, 5 years | −85.0% | −62.6% |
| Beta (5Y) | 1.87 | 1.41 |
| Employees | 106 | 601 |
| StockData Score | ||
| Total score | 11 (better) | 3 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 29.3× | – |
| P/S | 1.1× (better) | 22.6× |
| P/B | – | 6.3× |
| EV/EBITDA | 10.8× | – |
| FCF yield | −68.7% | −20.6% (better) |
| Fair value | $2.07 | $5.88 |
| Margin of safety | 1.1% (better) | −202% |
| Growth | ||
| Revenue growth (TTM) | 357% (better) | −58.3% |
| Revenue growth, 5Y average | 135% (better) | 25.9% |
| Profitability | ||
| Operating margin | 2.1% (better) | −475% |
| Net margin | 8.4% (better) | −453% |
| FCF margin | −74.6% (better) | −466% |
| Return on equity | – | −114% |
| Financial health | ||
| Interest coverage | – | −43.2× |
| Current ratio | 4.24 (better) | 3.34 |
| Altman Z-score | −2.66 | −1.30 (better) |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −12.3% |
| Shareholder yield | 0.00% (better) | −12.3% |
| Ownership | ||
| Held by institutions | 75.6% | 96.3% |
| Held by insiders | 36.3% | 31.7% |
| Insider net buying, 12 months | – | −$9.3M |
| Short interest, % of float | 6.0% | 15.2% |
Go deeper
- FHTX stock overview
- FHTX income statement
- FHTX valuation and score
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.